Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma (MM) after Prior Proteasome Inhibitor (PI) and Immunomodulatory Drug (IMiD) Treatment

Autor: Clemens, P.L., Yan, X., Puchalski, T., Lokhorst, H.M., Lonial, S., Losic, N., Khan, I., Jansson, R., Ahmadi, T., Lantz, K., Zhou, H., Xu, X.S.
Zdroj: In Clinical Lymphoma Myeloma and Leukemia September 2015 15 Supplement 3:e269-e270
Databáze: ScienceDirect
Externí odkaz: